K. H. Antonin

1.2k total citations
36 papers, 954 citations indexed

About

K. H. Antonin is a scholar working on Cellular and Molecular Neuroscience, Psychiatry and Mental health and Pharmacology. According to data from OpenAlex, K. H. Antonin has authored 36 papers receiving a total of 954 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Cellular and Molecular Neuroscience, 8 papers in Psychiatry and Mental health and 7 papers in Pharmacology. Recurrent topics in K. H. Antonin's work include Epilepsy research and treatment (6 papers), Analytical Methods in Pharmaceuticals (4 papers) and Amino Acid Enzymes and Metabolism (3 papers). K. H. Antonin is often cited by papers focused on Epilepsy research and treatment (6 papers), Analytical Methods in Pharmaceuticals (4 papers) and Amino Acid Enzymes and Metabolism (3 papers). K. H. Antonin collaborates with scholars based in Germany, Switzerland and United States. K. H. Antonin's co-authors include P. R. Bieck, Ulrich Klotz, Rainer Schulz, Erika Schmidt, C. H. Gleiter, Amy Racine-Poon, Gérard Flesch, J G Hastewell, Martin Mackay and Eric Nilsson and has published in prestigious journals such as Journal of Pharmacology and Experimental Therapeutics, International Journal of Pharmaceutics and Psychopharmacology.

In The Last Decade

K. H. Antonin

34 papers receiving 835 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
K. H. Antonin Germany 16 261 229 226 203 142 36 954
P. R. Bieck Germany 19 225 0.9× 96 0.4× 320 1.4× 310 1.5× 165 1.2× 73 1.2k
L Paalzow Sweden 24 221 0.8× 312 1.4× 213 0.9× 223 1.1× 185 1.3× 66 1.6k
Louis L. Radulovic United States 16 224 0.9× 219 1.0× 171 0.8× 128 0.6× 74 0.5× 25 973
D. R. Stanski United States 18 143 0.5× 195 0.9× 155 0.7× 295 1.5× 87 0.6× 58 1.8k
H. Friedman United States 24 204 0.8× 156 0.7× 228 1.0× 341 1.7× 227 1.6× 53 1.3k
T. Aaes‐Jørgensen Denmark 13 270 1.0× 93 0.4× 123 0.5× 249 1.2× 200 1.4× 24 820
C Crevoisier Switzerland 17 148 0.6× 162 0.7× 84 0.4× 133 0.7× 143 1.0× 40 888
J S Harmatz United States 16 228 0.9× 173 0.8× 123 0.5× 192 0.9× 336 2.4× 22 1.0k
Edward J. Randinitis United States 18 246 0.9× 371 1.6× 97 0.4× 194 1.0× 232 1.6× 43 1.3k
Edward J. Antal United States 19 174 0.7× 165 0.7× 71 0.3× 306 1.5× 280 2.0× 50 1.2k

Countries citing papers authored by K. H. Antonin

Since Specialization
Citations

This map shows the geographic impact of K. H. Antonin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by K. H. Antonin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites K. H. Antonin more than expected).

Fields of papers citing papers by K. H. Antonin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by K. H. Antonin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by K. H. Antonin. The network helps show where K. H. Antonin may publish in the future.

Co-authorship network of co-authors of K. H. Antonin

This figure shows the co-authorship network connecting the top 25 collaborators of K. H. Antonin. A scholar is included among the top collaborators of K. H. Antonin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with K. H. Antonin. K. H. Antonin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Schmidt, Erika, K. H. Antonin, Gérard Flesch, & Amy Racine-Poon. (1998). An interaction study with cimetidine and the new angiotensin II antagonist valsartan. European Journal of Clinical Pharmacology. 53(6). 451–458. 34 indexed citations
3.
Gleiter, C. H., et al.. (1994). Monoamine oxidase inhibition by the MAO-A inhibitors brofaromine and clorgyline in healthy volunteers. Journal of Neural Transmission. 95(3). 241–245. 9 indexed citations
4.
Bieck, P. R., et al.. (1993). Clinical pharmacology of reversible monoamine oxidase-A inhibitors.. PubMed. 16 Suppl 2. S34–41. 9 indexed citations
5.
Reimann, I. W., et al.. (1993). Oxaprotiline: enantioselective noradrenaline uptake inhibition indicated by intravenous amine pressor tests but not ?2-adrenoceptor binding to intact platelets in man. European Journal of Clinical Pharmacology. 44(1). 93–95. 2 indexed citations
6.
Kucher, Klaus, et al.. (1993). Role of cytochrome P4502D6 in the metabolism of brofaromine. European Journal of Clinical Pharmacology. 45(3). 265–269. 15 indexed citations
7.
Antonin, K. H., et al.. (1992). CLINICAL PHARMACOLOGY OF REVERSIBLE MAO-A INHIBITORS. Clinical Neuropharmacology. 15. 345A–346A. 1 indexed citations
8.
Reimann, I. W., et al.. (1992). Intravenous amine pressor tests in healthy volunteers. European Journal of Clinical Pharmacology. 42(2). 137–141. 12 indexed citations
9.
Gleiter, C. H., et al.. (1992). Effect of the selective MAO-A inhibitors brofaromine, clorgyline and moclobemide on human platelet MAO-B activity. Journal of Neural Transmission. 89(1-2). 129–133. 8 indexed citations
10.
Reimann, I. W., C. H. Gleiter, Marc Jobert, et al.. (1991). Human pharmaco-EEG of the reversible and selective MAO-A inhibitor brofaromine — comparison of different modes of data handling and statistical evaluation. European Neuropsychopharmacology. 1(3). 476–476. 2 indexed citations
11.
Bieck, P. R., et al.. (1989). Monoamine oxidase inhibition by phenelzine and brofaromine in healthy volunteers. Clinical Pharmacology & Therapeutics. 45(3). 260–269. 35 indexed citations
12.
Schulz, Rainer, et al.. (1989). Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline. Clinical Pharmacology & Therapeutics. 46(5). 528–536. 47 indexed citations
13.
Bieck, P. R. & K. H. Antonin. (1989). Tyramine potentiation during treatment with MAO inhibitors: brofaromine and moclobemide vs irreversible inhibitors.. PubMed. 28. 21–31. 50 indexed citations
14.
Bieck, P. R. & K. H. Antonin. (1988). Oral tyramine pressor test and the safety of monoamine oxidase inhibitor drugs: comparison of brofaromine and tranylcypromine in healthy subjects.. PubMed. 8(4). 237–45. 54 indexed citations
15.
Bieck, P. R., et al.. (1988). Evidence for “Local” gastrointestinal effects of MAO inhibition on metabolism and transport of tyramine in human subjects. Pharmacological Research Communications. 20. 129–130. 4 indexed citations
16.
Gleiter, Christoph H., et al.. (1988). Interaction of Alcohol and Transdermally Administered Scopolamine. The Journal of Clinical Pharmacology. 28(12). 1123–1127. 1 indexed citations
17.
Reimann, I. W., et al.. (1987). Influence of oestradiol on alpha2-adrenoceptor binding sites on intact platelets of young male volunteers. European Journal of Clinical Pharmacology. 33(2). 147–150. 2 indexed citations
18.
Gleiter, Christoph H., K. H. Antonin, & P. R. Bieck. (1984). Transdermally applied scopolamine does not impair psychomotor performance. Psychopharmacology. 83(4). 397–398. 5 indexed citations
19.
Klotz, Ulrich, K. H. Antonin, & P. R. Bieck. (1977). Cyclic nucleotide phosphodiesterases of human and rat gastric mucosa. Naunyn-Schmiedeberg s Archives of Pharmacology. 296(2). 187–190. 2 indexed citations
20.
Klotz, Ulrich & K. H. Antonin. (1977). Pharmacokinetics and bioavailability of sodium valproate. Clinical Pharmacology & Therapeutics. 21(6). 736–743. 170 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by P. R. Bieck Breakdown of academic impact, for papers by L Paalzow Breakdown of academic impact, for papers by Louis L. Radulovic Breakdown of academic impact, for papers by D. R. Stanski Breakdown of academic impact, for papers by H. Friedman Breakdown of academic impact, for papers by T. Aaes‐Jørgensen Breakdown of academic impact, for papers by C Crevoisier Breakdown of academic impact, for papers by J S Harmatz Breakdown of academic impact, for papers by Edward J. Randinitis Breakdown of academic impact, for papers by Edward J. Antal
Rankless by CCL
2026